Changes confirmed

Scheduling decisions for cetirizine, budesonide confirmed despite Guild opposition The Therapeutic Goods Administration's delegate has confirmed previous interim decisions made by the June 2022 meeting of the Advisory Committee on Medicines Scheduling (ACMS) on changes to the scheduling of the anthistamine cetirizine and the corticosteroid budesonide. The ACMS decision has lowered the age at which